109 related articles for article (PubMed ID: 10360608)
1. Evaluation of Tomudex in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group study.
Samlowski WE; Lew D; Kuebler PJ; Kolodziej MA; Medina JE; Mangan KF; Moore DF; Schuller DE; Ensley JF
Invest New Drugs; 1998-1999; 16(3):271-4. PubMed ID: 10360608
[TBL] [Abstract][Full Text] [Related]
2. Open label, multi-centre phase II study of raltitrexed ('Tomudex') in patients with inoperable squamous-cell carcinoma of head and neck.
Clarke SJ; Zalcberg J; Olver I; Mitchell PL; Rischin D; Dalley D; Green M; Davidson YE
Ann Oncol; 2000 Feb; 11(2):239-41. PubMed ID: 10761765
[TBL] [Abstract][Full Text] [Related]
3. S-1 monotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck after progression on platinum-based chemotherapy.
Yokota T; Onozawa Y; Boku N; Hamauchi S; Tsushima T; Taniguchi H; Todaka A; Machida N; Yamazaki K; Fukutomi A; Yasui H
Jpn J Clin Oncol; 2011 Dec; 41(12):1351-7. PubMed ID: 21980053
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of gemcitabine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group phase II study.
Samlowski WE; Gundacker H; Kuebler JP; Giguere JK; Mills GM; Schuller DE; Ensley JF
Invest New Drugs; 2001; 19(4):311-5. PubMed ID: 11561690
[TBL] [Abstract][Full Text] [Related]
5. Clinical trials referral resource. Clinical trials with tomudex.
Sorensen JM; Cheson BD; Phillips PH
Oncology (Williston Park); 1996 Jul; 10(7):1041-2. PubMed ID: 8837120
[No Abstract] [Full Text] [Related]
6. Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.).
Galetta D; Giotta F; Rosati G; Gebbia V; Manzione L; Di Bisceglie M; Borsellino N; Colucci G
Anticancer Res; 2005; 25(6C):4445-9. PubMed ID: 16334124
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of raltitrexed (Tomudex) in chemotherapy-pretreated patients with advanced colorectal cancer. Tomudex Cooperative Study Group.
Sato A; Kurihara M; Horikoshi N; Aiba K; Kikkawa N; Shirouzu K; Mitachi Y; Sakata Y; Wakui A
Anticancer Drugs; 1999 Sep; 10(8):741-8. PubMed ID: 10573207
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma.
Guo B; Cao S; Tóth K; Azrak RG; Rustum YM
Clin Cancer Res; 2000 Feb; 6(2):718-24. PubMed ID: 10690558
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
Cohen EE; Rosen F; Stadler WM; Recant W; Stenson K; Huo D; Vokes EE
J Clin Oncol; 2003 May; 21(10):1980-7. PubMed ID: 12743152
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of raltitrexed (Tomudex) in advanced pancreatic and biliary carcinoma.
François E; Hebbar M; Bennouna J; Mayeur D; Perrier H; Dorval E; Martin C; Bourgeois H; Barthélemy P; Douillard JY
Oncology; 2005; 68(4-6):299-305. PubMed ID: 16020956
[TBL] [Abstract][Full Text] [Related]
11. ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group.
Zalcberg JR; Cunningham D; Van Cutsem E; Francois E; Schornagel J; Adenis A; Green M; Iveson A; Azab M; Seymour I
J Clin Oncol; 1996 Mar; 14(3):716-21. PubMed ID: 8622016
[TBL] [Abstract][Full Text] [Related]
12. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Soulières D; Faivre S; Mesía R; Remenár É; Li SH; Karpenko A; Dechaphunkul A; Ochsenreither S; Kiss LA; Lin JC; Nagarkar R; Tamás L; Kim SB; Erfán J; Alyasova A; Kasper S; Barone C; Turri S; Chakravartty A; Chol M; Aimone P; Hirawat S; Licitra L
Lancet Oncol; 2017 Mar; 18(3):323-335. PubMed ID: 28131786
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study.
Caponigro F; Rosati G; De Rosa P; Avallone A; De Rosa V; De Lucia L; Comella P; Comella G
Oncology; 2002; 63(3):232-8. PubMed ID: 12381902
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
Caponigro F; Avallone A; McLeod H; Cartenì G; De Vita F; Casaretti R; Morsman J; Blackie R; Budillon A; De Lucia L; Gravina A; Catalano G; Comella P; Comella G
Clin Cancer Res; 1999 Dec; 5(12):3948-55. PubMed ID: 10632324
[TBL] [Abstract][Full Text] [Related]
15. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Cohen EE; Kane MA; List MA; Brockstein BE; Mehrotra B; Huo D; Mauer AM; Pierce C; Dekker A; Vokes EE
Clin Cancer Res; 2005 Dec; 11(23):8418-24. PubMed ID: 16322304
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens.
Blay JY; Judson I; Rodenhuis S; Hermans C; Smith M; van Glabbeke M; Verweij J
Anticancer Drugs; 1999 Nov; 10(10):873-7. PubMed ID: 10630354
[TBL] [Abstract][Full Text] [Related]
18. Interaction of tomudex with radiation in vitro and in vivo.
Teicher BA; Ara G; Chen YN; Recht A; Coleman CN
Int J Oncol; 1998 Sep; 13(3):437-42. PubMed ID: 9683775
[TBL] [Abstract][Full Text] [Related]
19. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Vermorken JB; Clement PM; Gauler T; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Cohen EE;
Lancet Oncol; 2015 May; 16(5):583-94. PubMed ID: 25892145
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
